The Greater Cannabis Company, Inc. (GCAN)
OTCMKTS · Delayed Price · Currency is USD
0.3349
+0.1149 (52.23%)
At close: Jul 31, 2026
The Greater Cannabis Company Company Description
The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics.
It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body.
The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson’s disease, Alzheimer’s disease, and other neuropsychiatric disorders.
The Greater Cannabis Company, Inc. was founded in 2014 and is based in Baltimore, Maryland.
The Greater Cannabis Company, Inc.
| Country | United States |
| Founded | 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Porfirio Sanchez-Talavera |
Contact Details
Address: 2833 Smith Avenue Baltimore, Maryland 21209 United States | |
| Phone | 443 738 4051 |
| Website | gcanrx.com |
Stock Details
| Ticker Symbol | GCAN |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US3916571033 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Porfirio Sanchez-Talavera | Chief Executive Officer and Chairman of the Board |
| Motti Stenge | Chief Operating Officer |
| Dr. Adi Aran M.D. | Chief Scientific Advisor |